thelancet.com
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de...
Two plasma-based metabolic signatures showed significant improvement in performance
compared with CA 19-9 alone in excluding pancreatic ductal adenocarcinoma in a prospective
real-world cohort. These ...